Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adenosine A2a receptor |
| Gene Name | ADORA2A |
| Uniprot | P29274 (Human); Q60613 (Mouse) |
| Synonym | A2aR; RDC8; ADORA2; adenosine receptor subtype A2a |
| Background | ADORA2A is encoded by ADORA2A gene. It belongs to the G-protein-coupled receptor (GPCR) family which has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. It is one of the four subtypes of adenosine receptors (A1R, A2AR, A2BR, A3R). ADORA2A possess seven transmembrane alpha helices and uses adenosine as the preferred endogenous agonist. Meanwhile, its structure reveals a ligand binding pocket distinct from that of other structurally determined GPCRs. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX482 | NativeExtract™ Human ADORA2A Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| S01YF-0423-KX16 | MemDX™ Human ADORA2A Membrane Protein in Membrane Nanoparticles (MNP), Full Length | HEK293 cell | Full length | MNP |
| S01YF-0423-KX131 | MemDX™ Membrane Protein Human ADORA2A (1-7; 67-77; 144-173; 259-266aa) Expressed in HEK293, C-Human Fc tag | HEK293 cell | Partial | N/A |
| Please for more products or customization | ||||
El***or: Ideal for GPCR signaling research requiring pharmacologically relevant responses.
23/Sep/2023
E***nd: Creative Biolabs delivered a truncated construct optimized for crystallization.
17/Feb/2024
ADORA2A Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
ADORA2A Knockout for Neuroprotection
Creative Biolabs offers ADORA2A knockout services for neuroprotection. ADORA2A antagonism is a promising strategy for mitigating neuroinflammation in Parkinson's disease (PD) and other neurodegenerative disorders. Gene editing systems enable precise disruption of the ADORA2A locus in microglia or astrocytes, reducing adenosine-mediated pro-inflammatory signaling. Preclinical studies in rodent models demonstrate that gene-edited cells exhibit diminished neurotoxic cytokine release, correlating with improved motor function and neuronal survival. Creative Biolabs' optimized RNA design and in vivo delivery protocols ensure high editing efficiency with minimal off-target effects, positioning this approach as a cornerstone for translational neuroprotective therapies.
AAV-Driven ADORA2A Overexpression in Cardiometabolic Disorders
Creative Biolabs offers AAV-driven ADORA2A overexpression services. Adeno-associated virus (AAV) vectors engineered for cardiac tropism can deliver ADORA2A transgenes to restore receptor expression in ischemic or hypertrophic myocardium. For instance, AAV9-mediated ADORA2A overexpression in murine models reduces infarct size by enhancing adenosine-dependent vasodilation and attenuating oxidative stress. Creative Biolabs' proprietary capsid engineering platform further refines tissue specificity, enabling therapeutic transgene expression exclusively in cardiomyocytes. Such precision aligns with the clinical demand for targeted interventions in heart failure and metabolic syndrome.
siRNA-Based ADORA2A Silencing in Oncology
Creative Biolabs offers siRNA-based ADORA2A silencing services. Systemic delivery of small interfering RNA (siRNA) conjugates targeting ADORA2A mRNA suppresses tumor immune evasion in checkpoint inhibitor-resistant cancers. Lipid nanoparticle (LNP)-encapsulated siRNAs, optimized for stability and lymphatic trafficking, have been shown to deplete ADORA2A in tumor-infiltrating T cells, revitalizing antitumor cytotoxicity. Creative Biolabs' siRNA design expertise, including chemical modifications for nuclease resistance and reduced immunogenicity, ensures robust in vivo target engagement. This modality is particularly compelling for combinatorial regimens with immunotherapies.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADORA2A cell therapy. Please for more services.
Chimeric Antigen Receptor (CAR) T Cells with ADORA2A Antagonism
Creative Biolabs offers CAR-T cell engineering services. Engineering CAR T cells to co-express ADORA2A-specific antibodies or shRNAs blocks adenosine-mediated immunosuppression within solid tumors. Preclinical data in glioblastoma models reveal that ADORA2A-suppressed CAR T cells exhibit enhanced persistence and tumor clearance, overcoming the adenosine-rich tumor microenvironment. Creative Biolabs' lentiviral vector systems enable stable integration of these modules, ensuring consistent receptor knockdown and functional potency during large-scale manufacturing.
Induced Pluripotent Stem Cell (iPSC)-Derived ADORA2A-Reprogrammed Astrocytes
Creative Biolabs offers iPSC-derived ADORA2A-reprogrammed astrocytes development services. iPSCs differentiated into astrocytes with ADORA2A overexpression secrete anti-inflammatory factors, such as IL-10, to counteract neuroinflammation in multiple sclerosis. These cells, when encapsulated in biocompatible scaffolds and implanted intracranially, demonstrate sustained receptor activity and reduced demyelination in preclinical models. Creative Biolabs' end-to-end differentiation protocols, including quality-controlled lineage-specific markers, guarantee therapeutic-grade cell products for clinical evaluation.
Tissue-Specific Viral Vectors for ADORA2A Modulation in Immune Cells
Creative Biolabs offers tissue-specific viral vectors development services for ADORA2A modulation in immune cells. Lentiviral vectors engineered with immune cell-specific promoters (e.g., CD4 or CD11c) enable conditional ADORA2A knockout in T regulatory cells or dendritic cells. This strategy amplifies antitumor immunity while sparing peripheral tissues from off-target effects. Creative Biolabs' validated promoter libraries and in vitro functional assays streamline vector optimization, ensuring clinically relevant specificity and safety profiles for autoimmune and oncologic applications.
Unlock the full potential of ADORA2A-targeted therapies through Creative Biolabs' integrated expertise in gene editing, viral vector engineering, and cell therapy development. Our tailored solutions are designed to accelerate your preclinical and clinical milestones. to strategize a precision-driven approach for your ADORA2A program, leveraging cutting-edge platforms that redefine therapeutic specificity and efficacy.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
